Abstract The polymerase chain reaction and direct sequencing were used to determine the nature of the mutations in the antithrombin III (AT3) gene in seven unrelated patients with familial antithrombin III (ATIII) deficiency and recurrent venous thrombosis. Three novel mutations were found, two associated with a type I deficiency state (Pro80---~Thr and His 120---~Tyr) manifesting reduced synthesis of ATIII. The other novel lesion (Met251---~Ile) was associated with a dysfunctional ATIII protein (type II ATIII deficiency) and is predicted to interfere either with a heparin-induced conformational change in the ATIII molecule or with docking to thrombin. A novel polymorphism (Tyr158--~Cys) was also found to occur in several individuals of Scandinavian origin.
Introduction
Antithrombin III (ATIII), a member of the superfamily of serine proteinase inhibitors (serpins), is the major physiological inhibitor of thrombin. It functions by providing an exposed reactive site that binds thrombin stably, a process greatly enhanced by heparin (Lane et al. 1992) . ATIII deficiency, which has a prevalence of between 1/5000 and 1/2000 in the general population, occurs in -5% of patients presenting with venous thrombosis (Blajchman et al. 1992) . Two main types of ATIII deficiency have been distinguished : In type I deficiency, both ATIII activity and antigen are reduced to the same extent whereas in type II deficiency, a higher level of ATIII antigen than activity is evident. The antithrombin III (AT3) gene, which comprises seven exons , is located on chromosome lq23-25 and encodes a mature secreted polypeptide of 432 amino acids. Nearly 40 different missense mutations have so far been reported in the AT3 gene ).
Materials and methods

Patient analysis
Thrombotic events experienced by seven putatively unrelated ATIII deficient patients are listed in Table 1 . ATIII activity was measured by a two-stage amidolytic method using the chromogenic substrate Th-1 (Immuno, Sevenoaks, UK). ATIII antigen measurement was performed by radial immunoassay using an ovine/rabbit antiserum to human ATIII (Behring Diagnostics, Hounslow, UK). ATIII activity and antigen values for each patient are listed in Table 1. DNA sequencing and restriction fragment length polymorphism analysis
The polymerase chain reaction (PCR)/direct sequencing was performed as described (Grundy et al. 1991) . Patients 4-7 were typed for the following AT3 gene polymorphisms: Pstl (Prochownik et al. 1983) , DdeI , 5" length (Wu et al. 1989) and Alu8 (ATI?), repeat (Olds et al. 1994 The crystal structure of cleaved bovine ATIII (Mourey et al. 1993 ; coordinates courtesy of L. Mourey) was docked with the crystal structure of human thrombin (Stubbs and Bode 1993;  coordinates from Protein Data Bank)using the BIOSYM software suite V.2.3.0 (BIOSYM, San Diego, CA) running on a Silicon Graphics Indigo Elan R4000. Native amino acids were then replaced by mutant residues and plausible explanations for their interference with ATIII structure, function or stability were sought based upon location, steric effects and structure/function relationships. 
Results and discussion
Seven putatively unrelated patients with heterozygous ATIII deficiency and a history of venous thrombotic disease were selected for study (Table 1) and their AT3 gene exon-containing fragments analysed by PCR/direct sequencing. The nature of the underlying genetic lesion was established in all seven cases; a total of four different single base-pair substitutions were found, three of which were novel (Fig. 1, Table 1 ).
In patient l, a heterozygous CCC-+ACC transversion in exon 2 was noted, which is predicted to result in the substitution of proline by threonine at amino acid residue 80. This lesion was also present in the patient's clinically and phenotypically affected mother but not in her normal brother. Pro80 is located within cz-helix B and is conserved in many serpins, including human plasminogen activator inhibitors (PAI) 1 and 2, cd-antitrypsin, c~l-antichymotrypsin, heparin cofactor II, C1 inhibitor, rat angiotensinogen and chicken ovalbumin (Ye et al. 1987) . Proline is known to promote helix formation if it occurs in the first turn of a potential o~-helix. The amino acid sequence in the immediate vicinity of the mutation (residues 77-82, FLSPLS) appears to be relatively indifferent to helix formation. In principle, the substituting residue, Thr, is also capable of promoting helix formation since its side chain may hydrogen band to the main chain. However, since in the crystal structure of ATIII, the side chain of Thr80 is buried in a moderately polar environment (Fig. 2) , it is unlikely to be able to do this, since the atoms of its sidechain would impact with the backbone and [3-carbon of Ala59. Taken together, these observations suggest that Pro80 is required for formation of c~-helix B; its substitution by Thr would prevent helix formation and thus normal protein folding, consistent with the observed state of type 1 deficiency.
In patient 2, a heterozygous CAC-+TAC transition in exon 3a was found that would substitute tyrosine for histidine at amino acid residue 120. This lesion was also detected in five phenotypically and/or clinically affected relatives but not in two normal relatives. Hisl20 is conserved in human heparin cofactor II, czl-antitrypsin, PAI-2 and chicken ovalbumin (Ye et al. 1987) . It is buried in a moderately polar environment within o~-helix D (Fig. 2) .
Both His and Tyr are polar and neutral with respect to helix formation. However, tyrosine possesses a six-carbonring side-chain and an additional hydroxyl group whose introduction is predicted to result in adverse steric interactions between Tyr120 and residues Lys91 and Leu92. The larger side-chain of Tyr120 is unlikely to be able to reorient itself so as to alleviate these adverse interactions; this would lead to improper protein folding and a type I deficiency state.
In patient 3, a heterozygous ATG---~ATA transition in exon 4 was detected that results in the substitution of methionine 251 by isoleucine. Met251 is as highly conserved evolutionarily as residue Pro80. No family members were available to confirm cosegregation of this lesion with the deficiency state. The Met251--~Ile substitution is associated with a type II deficiency state (Table 1) implying a dysfunctional protein. However, the reduced ATIII antigen level apparent in patient 3 suggests that protein stability is also affected. Both Met and Ile are hydrophobic amino acids of similar size. Met251 lies within [3-sheet 3C and rests in a solvent-accessible canyon on the thrombindocking face of the protein (Fig. 2) . Its substitution by Ile is predicted to result in minor adverse interactions between Ile251 and Arg235 (Fig. 2) . The conservative nature of this substitution and its surface location may account for the partial stability of the mutant protein. The mutation may interfere with ATIII function through an allosteric conformational change induced by heparin binding: Arg235 appears to lie on the binding path of heparin (Evans et al. 1992) and is adjacent to Lys 236, which becomes exposed upon heparin binding (Chang 1989) . Alternatively, the location of Met251 on the docking face of ATIII may indicate that the mutation interferes with docking to thrombin.
In the remaining four patients (nos. 4-7), an identical TCG---~TTG transition was detected converting Ser394 to Leu. Two examples of this reactive site mutation have been previously reported in American (Stephens et al. 1987) and Italian (Olds et al. 1989 ) ATII1 deficient patients. All four examples of this lesion reported here were of Danish origin, consistent with their being identical-bydescent but they could also have arisen by recurrent mutation since they occurred in a hypermutable CpG dinucleotide. Patients 4-7 were therefore typed for the intragenie PstI, Ddei and 5" length polymorphisms in order to 3" Fig. 1A -D Three novel missense mutations and the Tyr/Cys158 polymorphism in the AT3 gene detected by PCR/direct sequencing. A CCC---~ACC (Pro80--~Thr) substitution in patient 1 (antisense strand shown). C Control. B CAC--~TAC (Hisl20---)Tyr) substitution in patient 2 (sense strand shown). C Control. C ATG--~ATA (Met251---)Ile) substitution in patient 3 (sense strand shown). C Control. D C Homozygote for Tyr158 allele (TAC) P Heterozygote, Tyr/Cys158 (TAC/TGC) (sense strand shown) confirm or exclude identity-by-descent; the Leu variant cosegregated invariably with a (-), (+), (short) haplotype for these markers consistent with identity-by-descent. These patients were also typed for a highly informative (ATT)n copy number polymorphism and were shown to possess different alleles, consistent with a model of recurrent mutation. However, since a de novo mutation was observed in one of the families studied, this (ATT)n repeat may be highly mutable and therefore unreliable as a marker. We thus consider that the question of mutational origin for the Ser394---~Leu substitution should remain open.
In addition to these pathological lesions, a GTG---) GAG transversion converting valine at position -3 to glutamic acid was noted in patient 3. First described as ATIII Dublin ), this signal peptide variant is now considered to be a common neutral polymorphism .
A novel heterozygous TAC---~TGC variant (predicted to convert the wild-type Tyr158 residue to Cys in m-helix E) was also detected in patients 1, 3, 5 and 7. Tyrosine is conserved at this position in human PAI-1 and chicken ovalbumin (Ye et al. 1987) . However, since the substitution of Tyr by Cys is moderately conservative (both amino acids are polar and possess hydrophobic side chains) and since this variant did not cosegregate with the deficiency state/clinical phenotype in the pedigrees of patients 1, 5 and 7, it appears to be either a neutral polymorphism or of only minor pathological significance. Consistent with this view, molecular modelling indicates that, although Tyr158 is buried, the Cys variant does not engender any adverse steric interactions (Fig. 2) . Since this variant has not been previously reported in the now considerable number of ATIII-deficient patients whose mutational lesions have been characterized , its occurrence in 3/5 Danish patients tested was indicative of a 'private' polymorphism in the Danish population. Interestingly, it was also found in patient 1 of Manx extraction who inherited it from her phenotypically and clinically normal father. Genealogical analysis of this patient's paternal line revealed the ancient Manx surname, Gill, meaning a servant. The first recorded mention of this name was in the year 1134, well before the Isle of Man came under English control in the fourteenth century but some 300 years after the first Viking invasions (Quillian 1989) . These genealogical data are therefore consistent with the Tyr/ Cys 158 variant being an ancient polymorphism of Scandinavian origin. 
